These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18569446)

  • 1. Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator.
    Klegerman ME; Zou Y; McPherson DD
    J Liposome Res; 2008; 18(2):95-112. PubMed ID: 18569446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue plasminogen activator binds to human vascular smooth muscle cells by a novel mechanism. Evidence for a reciprocal linkage between inhibition of catalytic activity and cellular binding.
    Werner F; Razzaq TM; Ellis V
    J Biol Chem; 1999 Jul; 274(31):21555-61. PubMed ID: 10419460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin targeting of tissue plasminogen activator-loaded echogenic liposomes.
    Tiukinhoy-Laing SD; Buchanan K; Parikh D; Huang S; MacDonald RC; McPherson DD; Klegerman ME
    J Drug Target; 2007 Feb; 15(2):109-14. PubMed ID: 17365281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes.
    Tiukinhoy-Laing SD; Huang S; Klegerman M; Holland CK; McPherson DD
    Thromb Res; 2007; 119(6):777-84. PubMed ID: 16887172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
    Liang JF; Park YJ; Song H; Li YT; Yang VC
    J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA.
    Renatus M; Engh RA; Stubbs MT; Huber R; Fischer S; Kohnert U; Bode W
    EMBO J; 1997 Aug; 16(16):4797-805. PubMed ID: 9305622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.
    Runge MS; Bode C; Matsueda GR; Haber E
    Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
    Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
    J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.
    Liang JF; Li YT; Connell ME; Yang VC
    AAPS PharmSci; 2000; 2(1):E7. PubMed ID: 11741223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
    Jankun J; Skrzypczak-Jankun E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
    Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E
    Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes.
    Smith DA; Vaidya SS; Kopechek JA; Huang SL; Klegerman ME; McPherson DD; Holland CK
    Ultrasound Med Biol; 2010 Jan; 36(1):145-57. PubMed ID: 19900755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of tissue plasminogen activator to endothelial cells. The effect on functional properties. Localization of a ligand in the B-chain of tPA.
    Cheng XF; Brohlin M; Pohl G; Bäck O; Wallén P
    Thromb Res; 1995 Jan; 77(2):149-64. PubMed ID: 7740507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model.
    Laing ST; Moody MR; Kim H; Smulevitz B; Huang SL; Holland CK; McPherson DD; Klegerman ME
    Thromb Res; 2012 Oct; 130(4):629-35. PubMed ID: 22133272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An activated-platelet-sensitive nanocarrier enables targeted delivery of tissue plasminogen activator for effective thrombolytic therapy.
    Huang Y; Yu L; Ren J; Gu B; Longstaff C; Hughes AD; Thom SA; Xu XY; Chen R
    J Control Release; 2019 Apr; 300():1-12. PubMed ID: 30807804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro.
    Stringer KA; Lindenfeld J; Repine AJ; Cohen Z; Repine JE
    Inflammation; 1997 Feb; 21(1):27-34. PubMed ID: 9179619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.
    Absar S; Kwon YM; Ahsan F
    J Control Release; 2014 Mar; 177():42-50. PubMed ID: 24417965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid molecules: insights into plasminogen activator function.
    Runge MS; Bode C; Haber E; Quertermous T
    Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes.
    Shaw GJ; Meunier JM; Huang SL; Lindsell CJ; McPherson DD; Holland CK
    Thromb Res; 2009 Jul; 124(3):306-10. PubMed ID: 19217651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.